News &
Events
InSitu Biologics Announces Co-Development Agreement With Mayo Clinic
InSitu Biologics is pleased to announce that it has entered into an agreement with the Mayo Clinic to further develop its...
InSitu Biologics Shares Latest Investigational Work at ASRA Meeting
InSitu Biologics will share the latest investigational work on its multi-phase drug delivery matrix at the upcoming 21st Annual Pain...
InSitu Biologics Welcomes Dr. M. Yaman to Medical Advisory Board
InSitu Biologics is very pleased to announce the appointment of Dr. M. Yaman, FRCS, FACS, to its Medical Advisory Board. For more...
InSitu Biologics Shares Results at American Society of Regional Anesthesia Pain Meeting
InSitu Biologics will share the latest investigational work on its hydrogel-lipid-microparticle matrix at the upcoming 47th Annual...
InSitu Biologics Welcomed Into UAE in5 Incubator
InSitu Biologics was formally welcomed into in5, one of the UAE's leading incubators, last month by in5's Board of Directors. In5...
CEO Update: December 2021
InSitu Biologics is closing out 2021 with many accomplishments. We received positive pre-IND feedback from the FDA, made gains in...
INSB200™ Poster Chosen “Best Of Meeting” by ASRA Pain Meeting 2021
The American Society of Regional Anesthesia has chosen InSitu Biologics’ INSB200™ poster as a Best of Meeting presentation in Emerging...
CEO Update: August 2021
InSitu Biologics has had a very productive summer. We received positive pre-clinical animal study results on our lead product, had...
CEO Update: April 2021
InSitu Biologics is off to a fast start in 2021. We completed a successful financing round, made great strides in our R&D efforts,...
CEO Update: December 2020
Insitu Biologics had several key accomplishments in 2020, setting the stage for an even better 2021. We significantly reduced our...